Financing Costs. Financing costs for the nine months ended September 30, 2014 totaled $593,770, a decrease of $2,171,829, or 78.5% from $2,765,599 incurred during the nine months ended September 30, 2013. Financing costs are primarily related to the fees paid related to the issuance of our Series A and Series B Preferred Stock in 2011 and 2012 and a beneficial conversion feature in our Series C Preferred Stock. During the nine months ended September 30, 2014, we converted all the outstanding Series A and Series B preferred stock to common.
(0)
(0)
BioSig Technologies Inc. (BSGM) Stock Research Links